AKT1 and neoplasm: The fact that patients whose tumours carry an AKT1-E17K mutation have shown high response rates following treatment with the ATP-competitive-inhibitor-capivasertib suggests that, in a subset of patients, this mechanism of AKT activation can render tumours susceptible to AKT kinase inhibition.